|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-22
|
|
pubmed:abstractText |
The efficacy of recombinant interleukin-2 (rIL-2) was assessed in HIV-infected patients with advanced immune suppression and a discordant immune response to highly active antiretroviral therapy (HAART). The primary endpoint was median change in CD4+ T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0213-005X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
27-31
|
|
pubmed:meshHeading |
pubmed-meshheading:18208763-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:18208763-Adult,
pubmed-meshheading:18208763-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:18208763-CD4 Lymphocyte Count,
pubmed-meshheading:18208763-CD4-CD8 Ratio,
pubmed-meshheading:18208763-CD4-Positive T-Lymphocytes,
pubmed-meshheading:18208763-Cytokines,
pubmed-meshheading:18208763-Female,
pubmed-meshheading:18208763-Fever,
pubmed-meshheading:18208763-HIV Infections,
pubmed-meshheading:18208763-Humans,
pubmed-meshheading:18208763-Immunologic Factors,
pubmed-meshheading:18208763-Interleukin-2,
pubmed-meshheading:18208763-Lymphopenia,
pubmed-meshheading:18208763-Male,
pubmed-meshheading:18208763-Middle Aged,
pubmed-meshheading:18208763-Prospective Studies,
pubmed-meshheading:18208763-Recombinant Proteins,
pubmed-meshheading:18208763-Viral Load
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART.
|
|
pubmed:affiliation |
Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. mcrespo@vhebron.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
